Abstract
Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.
Original language | English (US) |
---|---|
Article number | 46 |
Journal | Journal of Hematology and Oncology |
Volume | 6 |
Issue number | 1 |
DOIs | |
State | Published - 2013 |
Keywords
- Diffuse large B cell lymphoma
- MAP kinase signaling
- NHL
- Sorafenib
ASJC Scopus subject areas
- Molecular Biology
- Hematology
- Oncology
- Cancer Research